42885-14-3

Basic information

• Product Name: 3-CYANO-5-METHYLPYRIDINE
• Synonyms: 3-CYANO-5-METHYLPYRIDINE;5-Cyano-3-picoline~5-Methylnicotinonitrile~5-Methylpyridine-3-carbonitrile;3-CYANO-5-METHYLPYRIDINE 98+%;5-Cyano-3-picoline;3-Cyano-5-methylpyridine, 5-Methylpyridine-3-carbonitrile;3-CYANO-5-METHYLPYRIDINE 5-METHYL-NICOTINONITRILE;3-CYANO-5-METHYLPYRIDINE (3-CYANO-5-PICOLINE);5-Methyl-3-pyridinecarbonitrile
• CAS NO: 42885-14-3
• Molecular Formula: C₇H₆N₂
• Molecular Weight: 118.14
• EINECS: 255-988-8
• Mol File: 42885-14-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 83-87 °C
• Boiling Point: 237.2 °C at 760 mmHg
• Flash Point: 93.7 °C
• Appearance: /
• Density: 1.08 g/cm³
• Vapor Pressure: 0.0453mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.08±0.20(Predicted)
• BRN: 111258
• CAS DataBase Reference: 3-CYANO-5-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CYANO-5-METHYLPYRIDINE(42885-14-3)
• EPA Substance Registry System: 3-CYANO-5-METHYLPYRIDINE(42885-14-3)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-37/38-41-36/37/38
• Safety Statements: 26-36/39-36
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 42885-14-3(Hazardous Substances Data)

Usage

General Description

3-CYANO-5-METHYLPYRIDINE is a chemical compound with the molecular formula C7H6N2. It is a heterocyclic compound with a pyridine ring substituted with a cyano group at the 3-position and a methyl group at the 5-position. 3-CYANO-5-METHYLPYRIDINE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in organic synthesis, particularly in the production of various functionalized pyridine derivatives. 3-CYANO-5-METHYLPYRIDINE is known for its potential biological activities and has been studied for its anti-cancer, antiviral, and antimicrobial properties. Additionally, it is used as a reagent in various chemical reactions and processes.

InChI:InChI=1/C7H6N2/c1-6-2-7(3-8)5-9-4-6/h2,4-5H,1H3

Upstream product

• 420-04-2 CYANAMID 
• 152803-03-7 propyl 5-methyl-3-pyridinecarboximidate 
• 591-22-0 3,5-Lutidine 
• 70-57-5 5-methylpyridinylcarboxamide 
• 143-33-9 sodium cyanide 

Downstream Products

• 29681-45-6 5-methylnicotinic acid methyl ester 
• 194468-04-7 5-methylpyridine-3-carboximidamide 
• 42972-46-3 1-(5-methylpyridin-3-yl)ethanone 
• 82111-06-6 (+/-)-5-Methylnicotine 
• 177660-92-3 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)-1H-imidazol-1-yl]benzenesulfonamide 
• 177660-88-7 3-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine 

Relevant articles and documents

TRIAZOLOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to triazolopyridyl compounds of the structural formula: [Formula should be inserted here] or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

A process for the preparation of 4-[2-(aryl or heterocyclo)-1H-imidazol-1-yl]benzenesulfonamides

A process to make a compound of the formula or a pharmaceutically acceptable salt thereof is disclosed wherein R3 is a radical selected from hydrido, alkyl, haloalkyl, aralkyl, heterocycloalkyl, heteroaralkyl, acyl, cyano, alkaxy, alkylthio, alkylthioalkyl, alkylsulfonyl, cycloalkylthio, cycloalkylthioalkyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl, haloalkylsulfonyl, arylsulfonyl, halo, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heterocyclocarbonyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-alkyl-N-arylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxycarbonyl, haloalkylcarbonyl, carboxyl, aminocarbonyl, alkylaminocarbonyl, alkylaminocarbonylalkyl, heteroarylalkoxyalkyl, heteroaryloxyalkyl, heteroarylthioalkyl, aralkoxy, aralkylthio, heteroaralkoxy, heteroaralkylthio, heteroarylalkylthioalkyl, heteroaryloxy, heteroarylthio, arylthioalkyl, aryloxyalkyl, arylthio, aryloxy, aralkylthioalkyl, aralkoxyalkyl, aryl and heteroaryl; wherein R4 is a radical selected from hydrido, alkyl and halo; and wherein R2 is selected from aryl and heterocyclo, wherein R2 is optionally substituted at a substitutable position with one or more radicals independently selected from alkylsulfonyl, aminosulfonyl, halo, alkylthio, alkyl, cyano, carboxyl, alkoxycarbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxy, amino, alkylamino, arylamino and nitro; ???said method comprising the steps of forming a (protected sulfonyl)benzenamine, treating said (protected sulfonyl)benzenamine first with a base and then with a nitrile to form an amidine, treating said amidine with a haloketone derivative in the presence of a base to form a hydroxyimidazole, forming a (protected sulfonylphenyl) imidazole by dehydrating said hydroxyimidazole, and forming said compounds by deprotecting said (protected sulfonylphenyl)imidazole.

1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation

A class of imidazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: STR1 wherein R1 -R6 are as described in the specification; or a pharmaceutically-acceptable salt thereof.